Mark Frydenberg, MD, of Australia's Monash University, discusses whether multiparametric MRI is ready to be used as a screening modality for prostate cancer.
Is multiparametric MRI at a point where urologists could use it as a screening modality for prostate cancer? In this interview, Mark Frydenberg, MD, of Monash University in Melbourne, Victoria, Australia, addresses this question and how the use of MRI is changing.
Also see - PET use in prostate cancer widens, but questions remain: An interview with Mark Frydenberg, MD
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.